JP2005506087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506087A5 JP2005506087A5 JP2003538376A JP2003538376A JP2005506087A5 JP 2005506087 A5 JP2005506087 A5 JP 2005506087A5 JP 2003538376 A JP2003538376 A JP 2003538376A JP 2003538376 A JP2003538376 A JP 2003538376A JP 2005506087 A5 JP2005506087 A5 JP 2005506087A5
- Authority
- JP
- Japan
- Prior art keywords
- dsrna
- strand
- helicase
- medicament
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108060004795 Methyltransferase Proteins 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 17
- 239000002773 nucleotide Substances 0.000 claims 16
- 125000003729 nucleotide group Chemical group 0.000 claims 16
- 230000003612 virological effect Effects 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 241000282472 Canis lupus familiaris Species 0.000 claims 8
- 239000003094 microcapsule Substances 0.000 claims 8
- 239000002088 nanocapsule Substances 0.000 claims 8
- 229920000642 polymer Polymers 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 241000711549 Hepacivirus C Species 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 6
- 241001493065 dsRNA viruses Species 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229920002477 rna polymer Polymers 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 5
- 239000004365 Protease Substances 0.000 claims 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 108010076039 Polyproteins Proteins 0.000 claims 4
- 108020000999 Viral RNA Proteins 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 239000000693 micelle Substances 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10155280 | 2001-10-26 | ||
| DE10158411 | 2001-11-29 | ||
| DE10160151A DE10160151A1 (de) | 2001-01-09 | 2001-12-07 | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| PCT/EP2002/000151 WO2002055692A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung |
| PCT/EP2002/000152 WO2002055693A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens |
| DE10235621 | 2002-08-02 | ||
| PCT/EP2002/011973 WO2003035876A1 (de) | 2001-10-26 | 2002-10-25 | Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506087A JP2005506087A (ja) | 2005-03-03 |
| JP2005506087A5 true JP2005506087A5 (enExample) | 2006-01-05 |
Family
ID=34799649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003538376A Withdrawn JP2005506087A (ja) | 2001-10-26 | 2002-10-25 | プラス鎖rnaウイルスによる感染症を処置するための2本鎖リボ核酸の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20050119202A1 (enExample) |
| JP (1) | JP2005506087A (enExample) |
| CN (1) | CN1608133A (enExample) |
| WO (1) | WO2003035876A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| PT1309726E (pt) * | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| DK1407044T4 (en) | 2000-12-01 | 2017-12-04 | Max-Planck-Gesellschaft Zur Förderung Der Wss E V | RNA interference mediating small RNA molecules |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US20050182007A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| US20050143333A1 (en) * | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
| DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
| US8729036B2 (en) * | 2002-08-07 | 2014-05-20 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
| US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
| US20070021365A1 (en) * | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
| FR2898908A1 (fr) | 2006-03-24 | 2007-09-28 | Agronomique Inst Nat Rech | Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence |
| ES2402334T3 (es) | 2007-08-02 | 2013-04-30 | Gilead Biologics, Inc | Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis |
| WO2009147684A2 (en) * | 2008-06-06 | 2009-12-10 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| CA2753338A1 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
| US9107935B2 (en) * | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
| EP2411413B1 (en) | 2009-03-23 | 2016-05-11 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
| AU2010284000A1 (en) * | 2009-08-21 | 2012-03-22 | Gilead Biologics, Inc. | In vitro screening assays |
| KR20120063488A (ko) | 2009-08-21 | 2012-06-15 | 길리아드 바이오로직스, 인크. | 리실 옥시다제 및 loxl2로부터의 촉매 도메인 |
| BR112012008111A2 (pt) * | 2009-08-21 | 2017-02-21 | Gilead Biologics Inc | métodos e composições para tratamento de desordens fibróticas pulmonares |
| AU2010284001A1 (en) * | 2009-08-21 | 2012-03-22 | Gilead Biologics, Inc. | Therapeutic methods and compositions |
| WO2011022670A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
| RU2549684C2 (ru) | 2010-02-04 | 2015-04-27 | Джилид Байолоджикс, Инк. | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
| CN110042099A (zh) | 2010-03-24 | 2019-07-23 | 菲奥医药公司 | 皮肤与纤维化症候中的rna干扰 |
| EP2550001B1 (en) | 2010-03-24 | 2019-05-22 | Phio Pharmaceuticals Corp. | Rna interference in ocular indications |
| AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
| KR101328568B1 (ko) | 2010-10-22 | 2013-11-13 | 성균관대학교산학협력단 | Rna 간섭을 유도하는 핵산 분자 및 그 용도 |
| EP2853597B1 (en) * | 2012-05-22 | 2018-12-26 | Olix Pharmaceuticals, Inc. | Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor |
| BR112016026699B1 (pt) | 2014-05-15 | 2022-09-13 | Insmed Incorporated | Uso de uma composição farmaceutica de amicacina ou de um sal farmaceuticamente aceitável desta |
| JP6726105B2 (ja) | 2014-12-15 | 2020-07-22 | 株式会社ボナック | TGF−β1発現抑制のための一本鎖核酸分子 |
| EP4454637A3 (en) | 2015-11-16 | 2025-01-08 | Olix Pharmaceuticals, Inc. | Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3 |
| US10519449B2 (en) | 2016-02-02 | 2019-12-31 | Olix Pharmaceuticals, Inc. | Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB |
| WO2017134525A1 (en) | 2016-02-02 | 2017-08-10 | Olix Pharmaceuticals, Inc. | TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4Rα, TRPA1, OR F2RL1 |
| KR102339886B1 (ko) | 2016-04-11 | 2021-12-17 | 올릭스 주식회사 | 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법 |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| WO2018146557A2 (en) | 2017-02-10 | 2018-08-16 | Dong Ki Lee | Long double-stranded rna for rna interference |
| US11571386B2 (en) | 2018-03-30 | 2023-02-07 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO1999062927A1 (en) * | 1998-06-05 | 1999-12-09 | Human Genome Sciences, Inc. | Connective tissue growth factor-4 |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| PT1309726E (pt) * | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| DK1407044T4 (en) * | 2000-12-01 | 2017-12-04 | Max-Planck-Gesellschaft Zur Förderung Der Wss E V | RNA interference mediating small RNA molecules |
-
2002
- 2002-10-25 WO PCT/EP2002/011973 patent/WO2003035876A1/de not_active Ceased
- 2002-10-25 CN CNA02826181XA patent/CN1608133A/zh active Pending
- 2002-10-25 US US10/493,686 patent/US20050119202A1/en not_active Abandoned
- 2002-10-25 JP JP2003538376A patent/JP2005506087A/ja not_active Withdrawn
- 2002-10-25 US US10/493,768 patent/US20040248835A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506087A5 (enExample) | ||
| JP5513126B2 (ja) | 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 | |
| JP2005512976A5 (enExample) | ||
| CN111557939A (zh) | 法匹拉韦在治疗冠状病毒感染方面的应用 | |
| CN111991401A (zh) | 一种化合物在治疗SARS-CoV-2感染中的应用 | |
| JP2010530423A (ja) | 免疫活性化剤を用いたウイルス感染の早期介入 | |
| JP2010511039A5 (enExample) | ||
| CN116459295A (zh) | 一种肺炎清化方及其应用 | |
| RU2678105C2 (ru) | Применение таурина для профилактики и/или лечения заболеваний, вызванных вирусами рода коронавирусов и/или рода ротавирусов | |
| CN1835765A (zh) | 治疗病毒感染的方法 | |
| WO2025218456A1 (zh) | 巴洛沙韦钠在治疗克里米亚-刚果出血热病毒感染方面的应用 | |
| CN115397410A (zh) | 用于治疗、预防或限制病毒感染发生的方法和组合物 | |
| CN1179726C (zh) | 柚皮苷在制备支持性治疗非典型性肺炎药物中的应用 | |
| JP2019510731A (ja) | 抗ウイルス薬およびウイルス感染症の治療方法 | |
| CN106562970B (zh) | Gs-9620的用途 | |
| Deanasa et al. | The potential of antisense oligonucleotides (ASO) through inhalation based on gold nanoparticle (AuNP) delivery system in inhibiting SARS-CoV-2 replication and transcription | |
| US20240415953A1 (en) | Oral therapeutic vaccine compositions, methods and treatment of covid | |
| CN110179785B (zh) | 魏特酮在制备治疗或预防手足口病药物中的应用 | |
| JP2005532038A5 (enExample) | ||
| CN118490680A (zh) | 瑞香素在制备治疗病毒性肺炎的药物中的应用 | |
| CN120459175A (zh) | 一种兽用防疫药物及其制备方法和应用 | |
| JP2005506385A5 (enExample) | ||
| CN112641918A (zh) | 姜粉在制备治疗病毒性感冒的药物中的应用 | |
| JP2001151692A (ja) | イヌパルボウイルス感染症治療方法および治療剤 | |
| Punetha et al. | Pathogenesis of SARS-CoV-2 and Important Insights on its Potent Inhibitors Remdesivir and Chloroquine-A Review |